Comparison of remission of metformin，pioglitazone and their combination on early abnormal glucose metabolism in patients with polycystic ovary syndrome

Liu Qicong; Liu Qing; Yao Huodi; Liu Dongfang

doi:10.13406/j.cnki.cyxb.003139

您当前的位置：

首页 >

文章列表页 >

Comparison of remission of metformin，pioglitazone and their combination on early abnormal glucose metabolism in patients with polycystic ovary syndrome

Views on gonadal diseases | 更新时间：2025-10-21

- Comparison of remission of metformin，pioglitazone and their combination on early abnormal glucose metabolism in patients with polycystic ovary syndrome
- Journal of Chongqing Medical University Vol. 47, Issue 11, Pages: 1359-1364(2022)
- 作者机构：
  
  重庆医科大学附属第二医院内分泌代谢科，重庆 400010
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003139
  CLC： R588.6
- Received：20 April 2022，
  
  Published：28 November 2022
- 稿件说明：
移动端阅览
刘其聪,刘清,姚火娣,等.二甲双胍、吡格列酮及其联合用药对缓解多囊卵巢综合征患者早期糖代谢异常的比较[J].重庆医科大学学报,2022,47(11):1359-1364.

Liu Qicong,Liu Qing,Yao Huodi,et al.Comparison of remission of metformin，pioglitazone and their combination on early abnormal glucose metabolism in patients with polycystic ovary syndrome[J].Journal of Chongqing Medical University,2022,47(11):1359-1364.
刘其聪,刘清,姚火娣,等.二甲双胍、吡格列酮及其联合用药对缓解多囊卵巢综合征患者早期糖代谢异常的比较[J].重庆医科大学学报,2022,47(11):1359-1364. DOI： 10.13406/j.cnki.cyxb.003139.

Liu Qicong,Liu Qing,Yao Huodi,et al.Comparison of remission of metformin，pioglitazone and their combination on early abnormal glucose metabolism in patients with polycystic ovary syndrome[J].Journal of Chongqing Medical University,2022,47(11):1359-1364. DOI： 10.13406/j.cnki.cyxb.003139.

摘要

目的

比较二甲双胍、吡格列酮、卡双平3种药物缓解多囊卵巢综合征（polycystic ovary syndrome，PCOS）患者早期糖代谢异常的情况，探讨临床有效治疗PCOS患者早期糖代谢异常的方案。

方法

选取2018年3月至2020年9月在重庆医科大学附属第二医院内分泌代谢病科门诊就诊的150名根据鹿特丹标准诊断为PCOS且同时合并糖代谢异常的患者作为研究对象。按照治疗药物不同分为3组，其中二甲双胍组（A组）50例采用二甲双胍治疗（1 500 mg/d），吡格列酮组（B组）50例采用吡格列酮治疗（30 mg/d）；卡双平组（C组）50例采用卡双平治疗（二甲双胍1 000 mg/d，吡格列酮30 mg/d）。观察3组治疗前后3个月空腹及餐后2 h血糖水平、糖化血红蛋白（hemoglobin A1c，HbA1c）、胰岛素抵抗指数（homeostasis model assessment-insulin resistance，HOMA-IR）、空腹胰岛素水平，并比较3组临床治疗效果，特别是缓解早期糖代谢异常的情况。

结果

吡格列酮组及卡双平组餐后2 h血糖、空腹胰岛素、HOMA-IR治疗前后的改善率、糖代谢异常缓解率均明显高于二甲双胍组（

0.05）。3组空腹血糖、HbA1c治疗前后的改善率均无统计学意义（

0.05）。

结论

吡格列酮及卡双平较二甲双胍对PCOS患者代谢治疗效果更佳，能够有效降低血糖水平，改善胰岛素抵抗，从而帮助PCOS患者早期糖代谢异常得到缓解，为临床治疗提供理论依据，提高PCOS患者远期生活质量。

Abstract

Objective

To compare the remission of early abnormal glucose metabolism in patients with polycystic ovary syndrome （PCOS） treated with metformin，pioglitazone and their combination，and to explore the effective clinical treatment of early abnormal glucose metabolism in patients with PCOS.

Methods

A total of 150 patients diagnosed with PCOS according to Rotterdam criteria accompanied with abnormal glucose metabolism were enrolled from the Department of Endocrinology and Metabolism of The Second Affiliated Hospital of Chongqing Medical University from March 2018 to September 2020. According to different treatment drugs，they were equally randomized into three groups：group A（50 patients） treated with metformin（1 500 mg/d），group B（50 patients） treated with pioglitazone（30 mg/d） and group C（50 patients） treated with their combination（metformin 1 000 mg/d，pioglitazone 30 mg/d）. The levels of fasting and 2 h postprandial blood glucose，hemoglobin A1c（HbA1c），homeostasis model assessment-insulin resistance（HOMA-IR），and fasting insulin were observed in the three groups before and after the three-month treatment，and the clinical treatment effects，especially the remission of early abnormal glucose metabolism，were evaluated in the three groups.

Results

The improvement rate of 2 h postprandial blood glucose，fasting insulin and HOMA-IR after the treatment，the remission rate of abnormal glucose metabolism in group B and C were significantly higher than those in group A（

0.05）.There were no significant differences in the improvement rate of the fasting blood glucose and HbA1c after the treatment among the three groups（

0.05）.

Conclusion

Pioglitazone and their combination have a better therapeutic effect on the metabolism of PCOS patients，which can effectively reduce blood glucose and improve insulin resistance，helping to alleviate the early abnormal glucose metabolism of PCOS patients，providing a theoretical basis for clinical treatment and improving the long-term quality of life of PCOS patients.

关键词

Keywords

references

Della Corte L ， Foreste V ， Barra F ， et al . Current and experimental drug therapy for the treatment of polycystic ovarian syndrome [J ] . Expert Opin Investig Drugs ， 2020 ， 29 （ 8 ）： 819 - 830 .

Teede HJ ， Misso ML ， Costello MF ， et al . Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome [J ] . Fertil Steril ， 2018 ， 110 （ 3 ）： 364 - 379 .

Kakoly NS ， Khomami MB ， Joham AE ， et al . Ethnicity，obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS：a systematic review and Meta-regression [J ] . Hum Reprod Update ， 2018 ， 24 （ 4 ）： 455 - 467 .

Cao CJ ， Qi YY ， Fang DM ， et al . Clinical study on polycystic ovary syndrome treated with Diane-35 and pioglitazone [J ] . Am J Transl Res ， 2021 ， 13 （ 11 ）： 12742 - 12749 .

Zeng X ， Xie YJ ， Liu YT ， et al . Polycystic ovarian syndrome：correlation between hyperandrogenism，insulin resistance and obesity [J ] . Clin Chimica Acta ， 2020 ， 502 ： 214 - 221 .

Li YJ ， Tan J ， Wang QY ， et al . Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome：a randomized controlled trial [J ] . Fertil Steril ， 2020 ， 113 （ 1 ）： 197 - 204 .

Tao T ， Zhang Y ， Zhu YC ， et al . Exenatide，metformin，or both for prediabetes in PCOS：a randomized，open-label，parallel-group controlled study [J ] . J Clin Endocrinol Metab ， 2020 ， 106 （ 9588 ）： e1420 - e1432 .

Anagnostis P ， Tarlatzis BC ， Kauffman RP . Polycystic ovarian syndrome（PCOS）：long-term metabolic consequences [J ] . Metabolism ， 2018 ， 86 ： 33 - 43 .

Pani A ， Gironi I ， Di Vieste G ， et al . From prediabetes to type 2 diabetes mellitus in women with polycystic ovary syndrome：lifestyle and pharmacological management [J ] . Int J Endocrinol ， 2020 ， 2020 ： 6276187 .

Persson S ， Elenis E ， Turkmen S ， et al . Higher risk of type 2 diabetes in women with hyperandrogenic polycystic ovary syndrome [J ] . Fertil Steril ， 2021 ， 116 （ 3 ）： 862 - 871 .

Ng NYH ， Jiang GZ ， Cheung LP ， et al . Progression of glucose intolerance and cardiometabolic risk factors over a decade in Chinese women with polycystic ovary syndrome：a case-control study [J ] . PLoS Med ， 2019 ， 16 （ 10 ）： e1002953 .

邹大进，张　征，纪立农 . 缓解2型糖尿病中国专家共识 [J ] . 中国糖尿病杂志， 2021 ， 29 （ 9 ）： 641 - 652 .

Zou DJ ， Zhang Z ， Ji LN . Chinese expert consensus on alleviating type 2 diabetes [J ] . Chin J Diabetes ， 2021 ， 29 （ 9 ）： 641 - 652 .

Cassar S ， Misso ML ， Hopkins WG ， et al . Insulin resistance in polycystic ovary syndrome：a systematic review and Meta-analysis of euglycaemic-hyperinsulinaemic clamp studies [J ] . Hum Reprod ， 2016 ， 31 （ 11 ）： 2619 - 2631 .

Shang YJ ， Zhou HF ， Hu MH ， et al . Effect of diet on insulin resistance in polycystic ovary syndrome [J ] . J Clin Endocrinol Metab ， 2020 ， 105 （ 10 ）： dgaa425 .

Cai ML ， Shao XW ， Xing F ， et al . Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome：a randomized，open-label，noninferiority trial [J ] . Diabetes Obes Metab ， 2022 ， 24 （ 2 ）： 312 - 320 .

Naderpoor N ， Shorakae S ， de Courten B ， et al . Metformin and lifestyle modification in polycystic ovary syndrome：systematic review and Meta-analysis [J ] . Hum Reprod Update ， 2015 ， 21 （ 5 ）： 560 - 574 .

Valsamakis G ， Lois K ， Kumar S ， et al . Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome（PCOS） [J ] . Hormones ， 2013 ， 12 （ 3 ）： 363 - 378 .

Group DPPR . Long-term safety，tolerability，and weight loss associated with metformin in the diabetes prevention program outcomes study [J ] . Diabetes Care ， 2012 ， 35 （ 4 ）： 731 - 737 .

Legro RS ， Arslanian SA ， Ehrmann DA ， et al . Diagnosis and treatment of polycystic ovary syndrome：an endocrine society clinical practice guideline [J ] . J Clin Endocrinol Metab ， 2013 ， 98 （ 12 ）： 4565 - 4592 .

DeFronzo RA ， Banerji M ， Bray GA ， et al . Actos now for the prevention of diabetes （ACT NOW） study [J ] . BMC Endocr Disord ， 2009 ， 9 （ 1 ）： 17 .

Xu YF ， Wu YX ， Huang Q . Comparison of the effect between pioglitazone and metformin in treating patients with PCOS：a Meta-analysis [J ] . Arch Gynecol Obstet ， 2017 ， 296 （ 4 ）： 661 - 677 .

Xing C ， Li CZ ， He B . Insulin sensitizers for improving the endocrine and metabolic profile in overweight women with PCOS [J ] . J Clin Endocrinol Metab ， 2020 ， 105 （ 9 ）： 2950 - 2963 .

Romualdi D ， Guido M ， Ciampelli M ， et al . Selective effects of pioglitazone on insulin and androgenabnormalities in normo- and hyperinsulinaemic obese patients withpolycystic ovarysyndrome [J ] . Hum Reprod ， 2003 ， 18 （ 6 ）： 1210 - 1218 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of metformin and rosiglitazone in the treatment of polycystic ovarian syndrome with insulin resistance

Clinical efficacy of Liraglutide combined with metformin in overweight or obese patients with PCOS

A mouse model of polycystic ovary syndrome with abnormal glucose and lipid metabolism induced by dihydrotestosterone combined with high-fat diet

Relationshipbetweenthechangesinirisinlevelandatherosclerosisindicesinpatientswithtype2diabetesmellitustreatedwithmetformin

Metformin reverses nicotine-induced gefitinib resistance by epithelial-mesenchymal transition

Related Author

SUN Yu-han

et al

Liao Mingyu

Shen Rufei

Liao Qian

Zhou Ling

Ran Chenxi

Li Xiaorong

Related Institution

重庆市第三人民医院内分泌科

Assistant Reproductive Centre,the First Affiliated Hospital,Chongqing Medical University

Department of Endocrinology,The Second Affiliated Hospital of Army Medical University

Department of Endocrinology,The First Affiliated Hospital of Army Medical University

Department of Endocrinology，Chongqing Traditional Chinese Medicine Hospital

⁰